Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in participants with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer participants treated with the chemotherapy drug called oxaliplatin.

Inclusion Criteria: * Any gastrointestinal cancer including colon, rectal, colorectal, pancreas, esophageal, or other (any stage) * Previously or currently receiving oxaliplatin -based chemotherapy. * Clinical symptoms of peripheral neuropathy noted in medical record and suspected to be secondary to oxaliplatin -based therapy. * Ability and willingness to understand and sign an informed consent. Exclusion Criteria: * Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of oxaliplatin chemotherapy. * Unable to provide history.